“We have continued to grow our manufacturing capacity and expand our services to the pharmaceutical and biotechnology industries,” said Wolfgang Burger, of PharmaZell, adding: “We believe that our strong revenue growth and diverse customer base is positioning our company as a significant API manufacturer and service provider.”
The new laboratory is the latest in a number of expansions undertaken at the plant, which was opened in 2007 as a production site for the active pharmaceutical ingredient (API), Mesalamine.
The addition of a hi-tech R&D facility followed in 2008, along with a team of 35 chemists with expertise in process development, analytical R&D and small scale synthesis.